


New Access to Unsaturated Keto Carba Sugars (Gabosines) Using an Intramolecular Nozaki–Kishi Reaction as the Key Step

André Lubineau* and Isabelle Billault

Laboratoire de Chimie Organique Multifonctionnelle (URA CNRS 462), Institut de Chimie Moléculaire, Université Paris-Sud, Bt 420, F-91405 Orsay Cedex, France


Received February 19, 1998

We report here the first synthesis of gabosine **1** in nine steps from tetra-*O*-benzyl-D-glucose **2** (Scheme 1). The gabosines, the majority of which are trihydroxylated cyclohexenone derivatives, have been isolated from *Streptomyces* strains.¹ These unsaturated keto carbasugars present a great structural diversity due to variations at three asymmetric centers and differing substitutions at C-2 or C-3 such as for example in **3** or **4**. Isolation of **10**



gabosines has been reported, and to these may be added the glyoxylase I inhibitor (COTC)² **5** and the antibiotic KD16-U1³ **6** (gabosine C). Several methods for the synthesis of **5** and **6** have been developed.^{4,5} Moreover, gabosine-related derivatives have been used as intermediates for the synthesis of biological active compounds (i.e., a L-fucosyl-transferase inhibitor,⁶ valienamine and derivatives,⁷ and a “pseudo sugar C-disaccharide”⁸). Considering their versatility as synthons, we are interested in developing a new general access to the gabosines

Scheme 1



Reagents and conditions : a) NaBH₄, THF/H₂O ; b) TBDMSCl, Pyr.; c) PCC, AcONa, MS 4A°, CH₂Cl₂ ; d) Ph₃PCHX (X = Cl or Br), THF ; e) N(Bu)₄F, THF ; f) DMP, CH₂Cl₂ for **14** ; Swern oxidation for **15** ; g) CrCl₂, NiCl₂ (0.1%), DMF ; h) PCC, AcONa, MS 4A°, CH₂Cl₂ ; i) BCl₃, CH₂Cl₂.

skeleton and have focused on the preparation of gabosine **1**,⁹ which could serve as a precursor of various glucosidase inhibitors. A key step in our synthesis was a Nozaki–Kishi mediated cyclization¹⁰ which provides a new and efficient access to functionalized cyclohexene derivatives.¹¹

Results and Discussion

Starting from tetra-*O*-benzyl-D-glucose **2**, the silylated D-glucitol **8** was prepared, upon sodium borohydride reduction¹² followed by silylation (Scheme 1). Oxidation of **8** with either PCC in the presence of AcONa¹³ or with the Dess–Martin periodinane¹⁴ (DMP) gave the L-sorbose derivative **9** (90%). This ketone reacted with chloromethylenetriphenylphosphorane¹⁵ at –70 °C in THF to give **10a/10b** in 92% yield, while the bromo analogue **11** was obtained in 74% yield by reaction of **9** with bromo-

(1) Bach, G.; Breiding-mack, S.; Grabley, S.; Hammann, P.; Hütter, K.; Thiericke, R.; Uhr, H.; Wink, J.; Zeck, A. *Liebigs Ann. Chem.* **1993**, 241–250.

(2) Takeuchi, T.; Chimura, H.; Hamada, M.; Umezawa, H. *J. Antibiot.* **1975**, 28, 737–742.

(3) Tatsuta, K.; Tsuchiya, T.; Mikami, N.; Umezawa, S.; Umezawa, H.; Naganawa, H. *J. Antibiot.* **1974**, 27, 579–586.

(4) (a) Mirza, S.; Molleyres, L.-P.; Vasella, A. *Helv. Chim. Acta* **1985**, 988–996. (b) Takayama, H.; Hayashi, K.; Koizumi, T. *Tetrahedron Lett.* **1986**, 27, 5509–5512. (c) Shing, T. K. M.; Tang, Y. *Tetrahedron* **1990**, 46, 6575–6584. (d) Yamakoshi, Y. N.; Ge, W.-Y.; Sugita, J.; Okayama, K.; Takahashi, T.; Koizumi, T. *Heterocycles* **1996**, 42, 129–133.

(5) Lygo, B.; Swiatyj, M.; Trabsa, H.; Voyle, M. *Tetrahedron Lett.* **1994**, 35, 4197–4200.

(6) Cai, S.; Stroud, M. R.; Hakomori, S.; Toyokuni, T. *J. Org. Chem.* **1992**, 57, 6693–6696.

(7) (a) Horii, S.; Fukase, H. European Patent EP 0240175B1, 1987. (b) Horii, S.; Kameda, Y.; Fukase, H. European Patent EP 0089812A1, 1983.

(8) Barbaud, C.; Bols, M.; Lundt, I.; Sierks, M. R. *Tetrahedron* **1995**, 51, 9063–9078.

(9) In ref 1, only the relative configuration of gabosine I has been determined, giving the possibility of either an *ido* or *gluco* configuration.

(10) CrCl₂ in the presence of catalytic amounts of NiCl₂. (a) Takai, K.; Taghashira, M.; Kuroda, T.; Oshima, K.; Utimoto, K.; Nozaki, H. *J. Am. Chem. Soc.* **1986**, 108, 6048–6050. (b) Jin, H.; Uenishi, J.-I.; Christ, W. J.; Kishi, Y. *J. Am. Chem. Soc.* **1986**, 108, 5644–5646.

(11) For a review on the conversion of carbohydrate derivatives into functionalized cyclohexanes and cyclopentanes, see: Ferrier R. J.; Middleton S. *Chem. Rev.* **1993**, 93, 2779–2831. For an alternative synthesis of cyclohexene derivatives, see: McIntosh M. C.; Weinreb S. M. *J. Org. Chem.* **1991**, 56, 5010–5012.

(12) Rao, V. S.; Perlin, A. S. *Can. J. Chem.* **1995**, 59, 333–338.

(13) Corey, E. J.; Suggs, J. W. *Tetrahedron Lett.* **1975**, 31, 2647–2650.

(14) (a) Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, 48, 4156–4158. (b) Meyer, S. D.; Schreiber, S. L. *J. Org. Chem.* **1994**, 59, 7549–7552.

(15) Miyano, S.; Izumi, Y.; Hashimoto, H. *J. Chem. Soc., Chem. Commun.* **1978**, 446–447.




Figure 1.

methylenetriphenylphosphorane.^{16,17} The Wittig reaction turned out to be very stereoselective,^{14,18} yielding exclusively the *Z*-isomer for the vinyl bromide **11** and a 98:2 *Z/E* mixture for the vinyl chlorides **10a/10b**. The presence of **10b** (*E*-isomer) in the mixture has been evidenced by a second vinylic proton NMR signal at δ 6.22. The configurations of **10a** and **11** were assigned on the basis of NOE data. The NOESY spectra of **10a/10b** and **11** show a NOE between the vinylic proton H-1 and the allylic proton H-7 and H-7' but not between H-1 and H-3, suggesting a *Z* configuration (Figure 1). The vinyl halogenides **10a** and **11** were then desilylated with tetrabutylammonium fluoride¹⁹ to afford the alcohols **12** (90%) and **13** (80%), respectively. Oxidation of **12**, with DMP,¹² and of **13**, under Swern conditions,²⁰ yielded the aldehydes **14**²¹ (70%) and **15** (89%). We failed to cyclize **14** under Barbier conditions,²² using magnesium as the metal. Turning to the more reactive bromide **15**, with lithium activation, the problem was not solved, and at room temperature no reaction was detected, while at 40 °C, a β -elimination occurred. The Nozaki–Kishi reaction¹⁰ is known to promote the addition of vinyl halogenides or triflate to aldehydes. Examples of macrocyclizations using this reagent have been reported,²³ but to the best of our knowledge it has never been applied to the synthesis of cyclohexenes. Very pleasingly, the Cr/Ni catalysis smoothly promoted the cyclization of the vinyl bromide **15** and gave **16a/16b**²⁴ in 61% yield. Oxidation of the allylic alcohols **16a/16b** with MnO₂²⁵ or the DMP¹² gave the enone **17**²⁶ in only moderate yields (ca. 50%). Better yields (76%) were obtained by using PCC in the presence of AcONa.¹¹ Debenzylation of **17**

(16) Matsumoto, M.; Kuroda, K. *Tetrahedron Lett.* **1980**, *21*, 4021–4024.

(17) While chloromethylenetriphenylphosphorane could be prepared at room temperature, the bromomethylenetriphenylphosphorane had to be prepared at much lower temperature (–5 °C) and had to be used immediately.

(18) (a) Just, G.; O'Connor, B. *Tetrahedron Lett.* **1988**, *29*, 753–756. (b) O'Donnell, M. J.; Arasappan, A.; Hornback, W. J.; Huffman, J. C. *Tetrahedron Lett.* **1990**, *31*, 157–160.

(19) Corey, E. J.; Venkateswarlu, A. *J. Am. Chem. Soc.* **1972**, *94*, 6190–6191.

(20) Mancuso, A. J.; Huang, S. L.; Swern, D. *J. Org. Chem.* **1978**, *43*, 2480–2483.

(21) Degradation of aldehyde **14** may be observed, even after two purifications by flash chromatography. It was rapidly used in the following cyclization step.

(22) (a) Barbier, P. *C.R. Acad. Sci. Paris* **1899**, 110–111. (b) Blomberg, C.; Hartog, F. A. *Synthesis* **1977**, 18–31. For cyclization using this reaction, see: Leroux, Y. *Bull. Soc. Chim. Fr.* **1968**, 359–364.

(23) (a) Schreiber, S. L.; Meyers, H. V. *J. Am. Chem. Soc.* **1988**, *110*, 5180–5200. (b) MacMillan, D. W. C.; Overman, L. E. *J. Am. Chem. Soc.* **1995**, *117*, 10391–10392.

(24) The (*1R*) diastereoisomer **16b** has been described: Schmidt, R. R.; Laesecke, K. *CH* **648** 326 A5, 1981.

(25) Hoeger, C. A.; Johnston, A. D.; Okamura, W. H. *J. Am. Chem. Soc.* **1987**, *109*, 4690–4698.

(26) For an other access to **17**, or of **17** with other protecting groups, see ref 7a and Paulsen, H.; VonDey, W. *Liebig Ann. Chem.* **1987**, 125–131.

by hydrogenolysis could not be envisaged, and we therefore used BCl₃²⁷ at –78 °C and obtained gabosine I **1** in 74% yield. In this latter step neither epimerization at C-6 or β -elimination were observed. Compound **1** was obtained as a hygroscopic brown solid compound which prevented us from getting a reliable melting point, but it was fully characterized through a high-resolution mass spectrum and ¹H and ¹³C NMR spectra which confirm its homogeneity and which were found to be identical to those already described.¹ Finally, the negative value of the specific rotation, although smaller than the reported one, gave indication that the natural compound¹ has the *gluco* configuration.

In conclusion, we have prepared gabosine I **1** in nine steps from tetra-*O*-benzyl-D-glucose via a Nozaki–Kishi reaction. The cyclization of vinyl bromide **15** using this reaction provides a novel and efficient access to functionalized cyclohexene derivatives. Moreover, this method could be extended in principle to other sugars and should allow the preparation of a large number of gabosine type compounds.

Experimental Section

General. Chemical shifts are reported in δ vs Me₄Si for ¹H NMR spectra and relative to the CDCl₃ resonance at 77.00 ppm for ¹³C NMR spectra. Solvents were distilled just before use: THF from sodium/benzophenone, CH₂Cl₂ and DMF from CaH₂. Oxygen free DMF was obtained by passing argon under ultrasound. Elemental analyses were performed at the service central de microanalyses du CNRS at Gif-sur-Yvette.

1-*O*-tert-Butyldimethylsilyl-2,3,4,6-tetra-*O*-benzyl-D-glucitol (8). Pyridine (90 mL) was added to a mixture of **7**¹⁰ (4.90 g, 9.04 mmol) and *t*-Bu(Me)₂SiCl (1.93 g, 10.8 mmol) at 0 °C. The reaction mixture was then slowly warmed to room temperature and stirred overnight. The mixture was then concentrated and the residue dissolved in CH₂Cl₂ (100 mL). The organic phase was washed with water (100 mL), filtered on phase separator filter, and then concentrated. Flash chromatography (hexane/AcOEt 9:1) of the residue (6.20 g) gave 5.72 g (97%) of **8** as colorless syrup. ¹H NMR (CDCl₃): δ 0.00 (s, 6H, (CH₃)₂-Si); 0.87 (s, 9H, (CH₃)₃C); 3.10 (br d, 1H, *J* = 4.5 Hz, OH); 3.61 (br d, 2H, *J* = 4.5 Hz, H-1, H1'); 3.66–3.90 (m, 5H, H-6, H-6', H-2, H-3, H-4); 3.98 (m, 1H, H-5); 4.47 (d, 1H, *J* = 12.0 Hz, PhCH); 4.53 (d, *J* = 12.0 Hz, 1H, PhCH); 4.55 (s, 2H, PhCH₂); 4.61 (d, *J* = 11.5 Hz, 1H, PhCH); 4.64 (s, 2H, PhCH₂); 4.73 (d, *J* = 11.5 Hz, 1H, PhCH); 7.15–7.40 (m, 20 H aromatic). ¹³C NMR (CDCl₃): δ -5.5, 18.1, 25.8, 62.8, 70.9, 71.1, 73.1, 73.3, 74.1, 77.41, 78.08, 79.60, 127.5–128.4, 138.0, 138.1, 138.2, 138.4. IR (neat): 3500 cm⁻¹ (OH). [α]_D²⁴ = +20 (c 1.75, CH₂Cl₂). Anal. Calcd for C₄₀H₅₂O₆Si (656.94): C, 73.13; H, 7.98. Found: C, 72.99; H, 7.97.

1,3,4,5-Tetra-*O*-benzyl-6-*O*-tert-butyldimethylsilyl-L-sorbose (9). A suspension of AcONa (2.25 g, 27.4 mmol), PCC (2.95 g, 13.6 mmol), and 4 Å molecular sieves (5.30 g) in CH₂Cl₂ (30 mL) was stirred for 1 h at room temperature; then a solution of **8** (3.00 g, 4.56 mmol) in CH₂Cl₂ (15 mL) was added. After 2 h, the mixture was diluted with Et₂O (90 mL) and hexane (45 mL) and the mixture was stirred for a further 15 min. The suspension was filtered through a silica gel (70–200 μ m) column which was further eluted with Et₂O (400 mL). The organic phase was concentrated to 100 mL, washed with water (100 mL), and then dried (MgSO₄). After evaporation, flash chromatography (hexane/AcOEt 9:1 with Et₃N 0.2%) of the residue (3.10 g) gave 2.55 g of **9** (89%) as colorless syrup. ¹H NMR (CDCl₃): δ 0.00 (s, 6H, (CH₃)₂Si); 0.85 (s, 9H, (CH₃)₃C); 3.60 (dd, 1H, *J* = 7.5, 12.0 Hz, H-6); 3.74 (m, 2H, H-6', H-5); 3.97 (t, 1H, *J* = 4.0 Hz, H-4); 4.18 (d, 1H, *J* = 17.5 Hz, H-1); 4.19 (d, 1H, *J* = 4.0 Hz, H-3); 4.26 (d, 1H, *J* = 17.5 Hz, H-1'); 4.39 (s, 2H, PhCH₂); 4.44 (d, 1H, *J* = 12.0 Hz, PhCH); 4.49 (d, 1H, *J* = 12.0 Hz, PhCH); 4.56 (d, 1H, *J*

(27) Williams, D. R.; Brown, D. L.; Benbow, J. W. *J. Am. Chem. Soc.* **1989**, *111*, 1923–1925.

= 18.0 Hz, PhCH); 4.59 (s, 2H, PhCH₂); 4.60 (d, 1H, *J* = 18.0 Hz, PhCH); 7.17–7.39 (m, 20H, H aromatic). ¹³C NMR (CDCl₃): δ -5.4, 18.1, 25.8, 62.4, 73.1, 73.3, 73.4, 74.2, 74.3, 79.1, 79.3, 81.7, 127.5–128.4, 137.0, 137.4, 137.6, 138.4, 207.00. IR (neat): 1731 cm⁻¹ (CO). [α]_D²⁵ = -2.9 (c 1.35, CH₂Cl₂). Anal. Calcd for C₄₀H₅₀O₆Si (654.94): C, 73.36; H, 7.70. Found: C, 73.58; H, 7.64.

1-Chloro-2-[(phenylmethoxy)methyl]-3,4,5-tris(phenylmethoxy)-6-*O*-*tert*-butyldimethylsilylhex-1-ene (10a/10b). A chloromethylenetriphenylphosphorane solution (0.3 M) was prepared just before its use as follows: A solution of potassium *tert*-butylate (411 mg, 3.66 mmol) in THF was added at 0 °C to a stirred suspension of chloromethylenetriphenylphosphonium chloride (1.06 g, 3.06 mmol) in THF (6.5 mL). After 1 h at 0 °C, the mixture was warmed to room temperature and kept under stirring for a further 1 h. The resulting solution of phosphorane was then added to a cooled (-70 °C) solution of **9** (1.00 g, 1.53 mmol) in THF (4.5 mL). After 2 h at -70 °C, the mixture was warmed to -30 °C (30 min) and pentane (75 mL) was added. The resulting suspension was filtered, and the filtrate was washed with H₂O (75 mL). The aqueous phase was extracted twice with pentane (2 × 75 mL). The combined organic phases were then dried (MgSO₄), filtered, and concentrated. Flash chromatography (hexane/AcOEt 95:5) of the residue (1.2 g) gave 0.973 g of **10a/10b** (*Z/E* 98:2) as a colorless syrup (92%). The ratio *Z/E* was determined by integration of both vinylic H-1 signals (*E*-isomer δ 6.22 ppm). ¹H NMR (CDCl₃): δ 0.00 (s, 6H, (CH₃)₂Si); 0.90 (s, 9H, (CH₃)₃C); 3.54 (dd, *J* = 5.0, 10.0 Hz, H-6); 3.63 (q, *J* = 5.0 Hz, H-5); 3.73 (dd, *J* = 5.0, 10.0 Hz, H-6'); 3.90 (dd, *J* = 5.0, 6.0 Hz, H-4); 4.16 (dd, *J* = 1.5, 14.0 Hz, H-7); 4.26 (dd, *J* = 1.5, 14.0 Hz, H-7'); 4.40 (d, *J* = 12.5 Hz, 1H, PhCH); 4.50 (s, 2H, PhCH₂); 4.55 (d, *J* = 12.5 Hz, 1H, PhCH); 4.66 (s, 2H, PhCH₂); 4.70 (s, 2H, PhCH₂); 4.99 (d, *J* = 6.0 Hz, H-3); 6.50 (br s, H-1); 7.20–7.40 (m, 20H, H aromatic). ¹³C NMR (CDCl₃): δ -5.4, 18.2, 25.9, 62.5, 68.8, 71.6, 72.9, 73.2, 75.4, 77.0, 79.8, 80.6, 118.85, 127.3–128.4, 137.4, 137.8, 138.5, 139.0. IR (neat): 2856, 2957, 3030, 3064, 3088 cm⁻¹ (CH aromatic and CH double bond). Anal. Calcd for C₄₁H₅₁O₅SiCl (687.39): C, 71.64; H, 7.48; Cl, 5.16. Found: C, 71.90; H, 7.58; Cl, 5.27.

1-Bromo-2-[(phenylmethoxy)methyl]-3,4,5-tris(phenylmethoxy)-6-*O*-*tert*-butyldimethylsilylhex-1-ene (11). A bromomethylenetriphenylphosphorane solution (3 M) was prepared just before its use as follows: To a suspension of bromomethylenephosphonium bromide (2.66 g, 6.10 mmol) in THF (14 mL) was added dropwise at -5 °C a 1 M potassium *tert*-butylate solution in 2-methylpropanol (6.1 mL). The resulting orange solution was then immediately added to a solution of **9** (2.00 g, 3.05 mmol) in THF (20 mL) at -70 °C. The reaction went to completion after adding two times more of the orange bromomethylenetriphenylphosphorane solution prepared in the same conditions. After the third addition, the mixture was slowly warmed to room temperature (2 h) and diluted with hexane (100 mL). The resulting suspension was filtered through a silica gel (70–200 μm) column which was further eluted with Et₂O (600 mL). The organic phase was concentrated and the residue triturated with hexane (3 × 150 mL). The resulting suspension was then filtered and concentrated. Flash chromatography (hexane/Et₂O 98:2 and then hexane/AcOEt 95:5) of the residue (2.21 g) gave 1.62 g of **11** (*Z*-isomer) as colorless syrup (74%). ¹H NMR (CDCl₃): δ 0.00 (s, 3H, (CH₃)₂Si); 0.05 (s, 3H, (CH₃)₂Si); 0.90 (s, 9H, (CH₃)₃C); 3.56 (dd, *J* = 4.5, 10.5 Hz, H-6); 3.65 (q, *J* = 4.5 Hz, H-5); 3.75 (dd, *J* = 4.5, 10.5 Hz, H-6'); 3.91 (t, *J* = 4.5 Hz, H-4); 4.16 (dd, *J* = 1.5, 12.0 Hz, H-7); 4.26 (dd, *J* = 12.0, 1.5 Hz, H-7'); 4.40 (d, *J* = 10.5 Hz, 1H, PhCH); 4.50 (s, 2H, PhCH₂); 4.55 (d, *J* = 10.5 Hz, 1H, PhCH); 4.66 (d, *J* = 10.5 Hz, 1H, PhCH); 4.70 (s, 2H, PhCH₂); 4.73 (d, *J* = 10.5 Hz, 1H, PhCH); 4.92 (d, *J* = 4.5 Hz, H-3); 6.65 (br s, H-1); 7.25–7.45 (m, 20H, H aromatic). ¹³C NMR (CDCl₃): δ -5.4, 18.2, 25.9, 62.5, 69.8, 71.6, 72.9, 73.3, 75.4, 78.9, 79.8, 80.6, 107.4, 127.3–128.4, 137.6, 137.9, 138.4, 138.9, 140.2. IR (neat): 2856, 2927, 2953, 3031, 3064, 3088 cm⁻¹ (CH aromatic and CH double bond). [α]_D²⁵ = -11.3 (c 1.5, CH₂Cl₂). Anal. Calcd for C₄₁H₅₁O₅SiBr (731.85): C, 67.29; H, 7.02. Found: C, 67.84; H, 6.99.

1-Chloro-2-[(phenylmethoxy)methyl]-3,4,5-tris(phenylmethoxy)-6-hydroxyhex-1-ene (12). A solution of TBAF in THF (1 M, 1.23 mL) was added at room temperature to a stirred solution of **10a/10b** (0.842 g, 1.23 mmol) in THF (11 mL). After

16 h, the mixture was concentrated and flash chromatography (hexane/AcOEt 8:2) of the crude residue (1.2 g) gave 0.64 g of pure **12** as colorless syrup (90%) with no trace of the *E*-isomer. ¹H NMR (CDCl₃): δ 3.42 (m, 1H, H-6); 3.60 (m, 1H, H-6'); 3.67 (q, 1H, *J* = 7.5 Hz, H-5); 3.86 (t, 1H, *J* = 7.5 Hz, H-4); 4.09 (dd, 1H, *J* = 1.5, 16.5 Hz, H-7); 4.25 (dd, 1H, *J* = 1.5, 16.5 Hz, H-7'); 4.33 (d, 1H, *J* = 13.5 Hz, PhCH); 4.44 (s, 2H, PhCH₂); 4.51 (d, 1H, *J* = 13.5 Hz, PhCH); 4.54 (d, 1H, *J* = 13.5 Hz, PhCH); 4.63 (d, 1H, *J* = 13.5 Hz, PhCH); 4.67 (d, 1H, *J* = 13.5 Hz, PhCH); 4.71 (d, 1H, *J* = 13.5 Hz, PhCH); 4.88 (d, 1H, *J* = 7.5 Hz, H-3); 6.43 (br s, 1H, H-1); 7.20–7.40 (m, 20H, H aromatic). ¹³C NMR (CDCl₃): δ 61.5, 68.8, 71.7, 72.9, 75.2, 76.1, 79.3, 80.4, 118.8, 127.59–128.46, 137.3, 137.5, 137.8, 137.9, 138.3. IR (neat): 3434 cm⁻¹ (OH). [α]_D²⁵ = -17 (c 1, CH₂Cl₂). Anal. Calcd for C₃₅H₃₇O₅Cl (572.50): C, 73.35; H, 6.51; Cl, 6.19. Found: C, 72.56; H, 6.51, Cl, 6.91.

1-Bromo-2-[(phenylmethoxy)methyl]-3,4,5-tris(phenylmethoxy)-6-hydroxyhex-1-ene (13). A solution (1 M) of TBAF in THF (1 M, 2.36 mL) was added to a stirred solution of **11** (1.55 g, 2.14 mmol) in THF (21 mL) at 0 °C. The solution was warmed slowly to room temperature and stirred overnight. Et₂O (75 mL) was added, and the organic phase was washed with water (100 mL), dried (MgSO₄), and concentrated. Flash chromatography (hexane/AcOEt 95:5) of the residue (1.59 g) gave 1.06 g of **13** as colorless syrup (80%). ¹H NMR (CDCl₃): δ 2.10 (br s, 1H, OH); 3.42 (m, 1H, H-6); 3.60 (m, 1H, H-6'); 3.68 (q, 1H, *J* = 5.0 Hz, H-5); 3.87 (dd, 1H, *J* = 4.0, 5.0 Hz, H-4); 4.07 (dd, 1H, *J* = 2.0, 14.0 Hz, H-7); 4.25 (dd, 1H, *J* = 2.0, 14.0 Hz, H-7'); 4.30 (d, 1H, *J* = 11.0 Hz, PhCH); 4.42 (s, 2H, PhCH₂); 4.50 (d, 1H, *J* = 11.0 Hz, PhCH); 4.53 (d, 1H, *J* = 11.0 Hz, PhCH); 4.58 (d, 1H, *J* = 11.0 Hz, PhCH); 4.70 (d, 1H, *J* = 11.0 Hz, PhCH); 4.71 (d, 1H, *J* = 11.0 Hz, PhCH); 4.79 (d, 1H, *J* = 4.0 Hz, H-3); 6.56 (br s, 1H, H-1); 7.18–7.40 (m, 20H, H aromatic). ¹³C NMR (CDCl₃): δ 61.5, 69.9, 71.6, 72.8, 72.90, 75.17, 78.0, 79.5, 80.3, 107.5, 127.5–128.3, 137.1, 137.8, 138.2, 140.3. IR (neat): 3500 cm⁻¹ (OH). [α]_D²⁵ = -25.9 (c 1.35, CH₂Cl₂). Anal. Calcd for C₃₅H₃₇O₅Br (617.58): C, 68.07; H, 6.04. Found: C, 67.98; H, 6.19.

6-Chloro-2,3,4-tris(phenylmethoxy)-5-[(phenylmethoxy)methyl]hex-5-enal (14). A solution of **12** (0.66 g, 1.15 mmol) in CH₂Cl₂ (3.5 mL) was added to a cooled (0 °C) solution of Dess–Martin periodinane (1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1*H*)-one) (0.98 g, 2.30 mmol) in CH₂Cl₂ (4 mL). The mixture was then brought to 10 °C, and wet CH₂Cl₂ (55 mL containing 1.15 mmol (1 equiv) of water) was added dropwise over 1 h. The mixture was then concentrated. Then, Et₂O (50 mL) was added, followed by a 1:1 mixture (50 mL) of saturated NaHCO₃ solution and sodium thiosulfate solution (20%). The mixture was then stirred for 20 min further. The two phases were separated, and the aqueous phase extracted twice with Et₂O (2 × 50 mL). The combined organic phases were washed with H₂O (100 mL), dried (MgSO₄), filtered, and then concentrated. Flash chromatography (hexane/AcOEt 9:1) of the crude residue (0.70 g) gave 0.47 g of **14** as a colorless syrup (70%) which was shown to be relatively unstable at room temperature. ¹H NMR (CDCl₃): δ 3.86 (d, 1H, *J* = 4.5 Hz, H-2); 4.02 (dd, 1H, *J* = 1.5, 13.0 Hz, H-7); 4.05 (t, 1H, *J* = 4.5 Hz, H-3); 4.25 (dd, 1H, *J* = 1.5, 13.0 Hz, H-7'); 4.33 (d, 1H, *J* = 14.5 Hz, PhCH); 4.41 (d, 1H, *J* = 14.5 Hz, PhCH); 4.45 (s, 2H, PhCH₂); 4.48–4.68 (4d, 4H, *J* = 14.5 Hz, 4 PhCH); 5.01 (d, 1H, *J* = 4.5 Hz, H-4); 6.40 (m, 1H, H-6); 7.15–7.40 (m, 20H, H aromatic); 9.54 (br s, 1H, H-1). ¹³C NMR (CDCl₃): δ 68.8, 72.1, 72.9, 73.2, 74.5, 76.0, 80.8, 81.5, 118.8, 127.6–128.3, 136.9, 137.2, 137.3, 139.7, 201.05. IR (neat): 1701 cm⁻¹ (CO).

6-Bromo-2,3,4-tris(phenylmethoxy)-5-[(phenylmethoxy)methyl]hex-5-enal (15). To a stirred solution of oxalyl chloride (86 μL, 1.10 mmol) in CH₂Cl₂ (3.5 mL) was added DMSO (0.38 mL) at -78 °C. After 15 min, a solution of **13** (334 mg, 0.54 mmol) in CH₂Cl₂ (1.25 mL) was added dropwise and the stirring was continued at the same temperature for 15 min before addition of NET₃ (7.56 × 10⁻¹ mL, 5.40 mmol). The mixture was then slowly warmed to room temperature, diluted with Et₂O (20 mL), washed with 0.1 M HCl (20 mL), water (20 mL), and brine (20 mL), and finally dried (MgSO₄). Flash chromatography (hexane/AcOEt 98:02 to 9:1) of the residue (0.34 g) gave 0.30 g of **15** as a colorless syrup (89%). ¹H NMR (CDCl₃): δ 3.85 (d, 1H, *J* = 4.5 Hz, H-2); 4.01 (dd, 1H, *J* = 2.0, 14.0 Hz, H-7); 4.07 (t, 1H, *J* = 4.5 Hz, H-3); 4.23 (dd, 1H, *J* = 2.0, 14 Hz, H-7'); 4.33

(d, 1H, $J = 11.0$ Hz, PhCH); 4.41 (d, 1H, $J = 11.0$ Hz, PhCH); 4.45 (s, 2H, PhCH₂); 4.50 (d, 1H, $J = 11.0$ Hz, PhCH); 4.58 (d, 1H, $J = 11.0$ Hz, PhCH); 4.59 (d, 1H, $J = 11.0$ Hz, PhCH); 4.67 (d, 1H, $J = 11.0$ Hz, PhCH); 4.93 (d, 1H, $J = 4.5$ Hz, H-4); 6.52 (br s, 1H, H-6); 7.10–7.40 (m, 20H, H aromatic); 9.60 (br s, 1H, H-1). ¹³C NMR (CDCl₃): δ 69.9, 72.2, 72.9, 73.1, 74.5, 77.9, 80.7, 81.3, 107.5, 127.5–128.4, 137.0, 137.2, 137.3, 139.8, 200.6. IR (neat): 1726 cm⁻¹ (CO). $[\alpha]^{23}_D = -18.7$ (c 1.55, CH₂Cl₂). Anal. Calcd for C₃₅H₃₅O₅Br·0.5H₂O (624.77): C, 67.31; H, 5.81. Found: C, 67.86; H, 5.82.

(1*R*,5*R*,5*S*,6*S*)-4,5,6-Tris(phenylmethoxy)-3-[(phenylmethoxy)methyl]cyclohex-2-enol (16a/16b). A stirred mixture of CrCl₂ (617 mg, 5 mmol) and NiCl₂ (0.1%) was dried under reduce pressure (≈ 30 mmHg) at 160 °C. After 1 h, the gray powder was cooled to room temperature and DMF (oxygen free, 5 mL) was added under argon. The resulting green suspension was stirred at room temperature for a further 30 min, before a solution of **15** (124 mg, 0.20 mmol) in DMF (oxygen free, 5 mL) was added. After 22 h of stirring at 40 °C, cold water (30 mL) was added, and the mixture was extracted with Et₂O (4 \times 30 mL). The combined organic phases were dried and concentrated. Flash chromatography (hexane/AcOEt 9:1) of the residue (118 mg) gave 65 mg of **16a/16b** (1/1 mixture) as a colorless syrup (61%). ¹H NMR (CDCl₃), data of (1*S*) **16a**: δ 2.60 (br d, 1H, OH); 3.60 (dd, 1H, $J = 4.2, 9.2$ Hz, H-6); 3.94 (d, 1H, $J = 12.0$ Hz, H-7); 4.06 (dd, 1H, $J = 7.0, 12.0$ Hz, H-5); 4.16 (br d, 1H, $J = 7.0$ Hz, H-4); 4.24 (br d, 1H, $J = 12.0$ Hz, H-7); 4.30 (m, 1H, H-2); 4.50 (d, 1H, $J = 11.0$ Hz, PhCH); 4.53 (d, 1H, $J = 11.0$ Hz, PhCH); 4.62–5.93 (6d, 6H, $J = 11.0$ Hz, 6 PhCH); 5.91 (br d, 1H, $J = 4.7$ Hz, H-2); 7.20–7.40 (m, 20H, H aromatic). ¹H NMR (CDCl₃), data of (1*R*) **16b**: δ 2.12 (br d, 1H, OH); 3.57 (dd, 1H, $J = 7.0, 10.0$ Hz, H-6); 3.85 (dd, 1H, $J = 7.0, 10.0$ Hz, H-5); 3.91 (br d, 1H, $J = 10$ Hz, H-7); 4.25 (br d, 1H, $J = 10.0$ Hz, H-7); 4.29 (br d, 1H, $J = 10.0$ Hz, H-4); 4.29–4.36 (m, 1H, H-2); 4.44 (d, 1H, $J = 11.0$ Hz, PhCH); 4.52 (d, 1H, $J = 11.0$ Hz, PhCH); 4.67–5.02 (6d, 6H, $J = 11.0$ Hz, 6 PhCH); 5.73 (br s, 1H, H-1); 7.18–7.40 (m, 20H, H aromatic). ¹³C NMR (CDCl₃), (1*R* and 1*S*): δ 65.0, 71.2, 69.9, 70.9, 72.2, 72.5, 72.8, 74.0, 74.6, 74.7, 74.9, 75.1, 78.7, 78.7, 79.0, 79.6, 83.5, 83.7, 124.6, 127.1, 127.7–128.6, 137.9, 138.0, 138.3, 138.5, 139.9, 139.7, 200.6. IR (neat): 3500 cm⁻¹ (OH). Anal. Calcd for C₃₅H₃₆O₅·0.25 H₂O (541.17): C, 77.68; H, 6.80; O, 15.52. Found: C, 77.52; H, 6.89; O, 15.49.

(4*R*,5*S*,6*R*)-4,5,6-Tris(phenylmethoxy)-3-[(phenylmethoxy)methyl]cyclohex-2-enone (17). A suspension of AcONa (245 mg, 3.0 mmol), PCC (323 mg, 1.5 mmol), and 4 Å molecular

sieves (1.80 g) in CH₂Cl₂ (5 mL) was stirred for 30 min at room temperature; then a solution of **16a/16b** (0.40 g, 0.75 mmol) in CH₂Cl₂ (45 mL) was added. After 2 h, Et₂O (15 mL) and hexane (7.5 mL) were added and the reaction mixture was stirred for 15 min. The resulting suspension was filtered through a silica gel (70–200 μ m) column which was further eluted with Et₂O (150 mL). The organic phase was then concentrated to 50 mL, washed with water (50 mL), dried (MgSO₄), and finally concentrated. Flash chromatography (hexane/AcOEt 93:3 to 95:5 with Et₃N 0.3%) of the residue (0.31 g) gave 305 mg of **17** as a colorless syrup (76%). ¹H NMR (CDCl₃): δ 4.05 (dd, 1H, $J = 7.0, 11.0$ Hz, H-5); 4.04 (d, 1H, $J = 10.0$ Hz, H-6); 4.08 (br d, 1H, $J = 16.0$ Hz, H-7); 4.27 (br d, 1H, $J = 16.0$ Hz, H-7); 4.38 (br d, 1H, $J = 7.0$ Hz, H-4); 4.51 (s, 2H, PhCH₂); 4.65–4.80 (3d, 3H, $J = 11.0$ Hz, 3 PhCH); 3.88–5.15 (3d, 3H, $J = 11.0$ Hz, 3 PhCH); 6.23 (q, 1H, $J = 1.5$ Hz, H-2); 7.20–7.47 (m, 20H, H aromatic). ¹³C NMR (CDCl₃): δ 68.9, 73.1, 74.4, 75.6, 75.7, 79.1, 83.9, 84.9, 123.88, 127.7–128.5, 137.4, 137.6, 137.7, 138.0, 159.1, 196.7. $[\alpha]^{28}_D = -9$ (c 1, CHCl₃) (lit. $[\alpha]^{23}_D = -12$ (c 1, CHCl₃)). Anal. Calcd for C₃₅H₃₄O₅: C, 78.63; H, 6.41; O, 14.96. Found: C, 77.93; H, 6.52; O, 15.18.

(4*R*,5*S*,6*R*)-4,5,6-Trihydroxy-3-(hydroxymethyl)cyclohex-2-enone (1). A solution (1 M) of BCl₃ in CH₂Cl₂ (2.25 mL) was added to a cooled solution (-70 °C) of **17** (0.30 g, 0.56 mmol) in CH₂Cl₂ (30 mL). The reaction mixture was then warmed slowly to 0 °C (2 h) and then cooled to -70 °C before addition of pyridine (1.45 mL, 18 mmol) and MeOH (0.730 mL, 18 mmol). The mixture was then warmed to room temperature and concentrated. Water (1 mL) was added to the residue, and the solution was passed first through a column of Dowex resin (1 \times 8) (HCO₃⁻ form) and then through a column of Dowex resin (1 \times 50) (H⁺ form). The aqueous phase was reduced to 10 mL, washed with Et₂O (10 mL), and then concentrated. Flash chromatography (AcOEt/2-propanol/H₂O 8:2:1) of the residue followed by filtration through a polyacrylamide gel column gave 72 mg of **1** as a hygroscopic brown solid (74%). ¹H NMR (CD₃OD): δ 3.59 (dd, 1H, $J = 8.4, 10.9$ Hz, H-5); 4.01 (d, 1H, $J = 10.9$ Hz, H-6); 4.32–4.50 (2d, 2H, 2H-7); 4.36 (m, 1H, H-4); 6.16 (q, 1H, $J = 2.0$ Hz, H-2). ¹³C NMR (CDCl₃): δ 62.0, 73.7, 78.1, 79.4, 121.3, 167.9, 199.4. $[\alpha]^{27}_D = -40$ (c 1, MeOH) (lit.¹ $[\alpha]^{20}_D = -61.4$ (c 1, MeOH)). EI-MS: M⁺ calcd = 174.0528; found 174.0524 (0.25), 156 (1.2), 138 (18.0), 126 (19.5), 114 (68.11), 96 (100), 68 (85.98).

JO980309P